Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.38 |
| ▸ | CNR1 | P21554 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062675 | 0.91 | CNR2 (0.40) | CNR2CNR1EGFR | |
| SCHEMBL13062669 | 0.89 | CNR2 (0.36) | CNR2CNR1EGFR | |
| SCHEMBL3660664 | 0.82 | CNR1 (0.56) | CNR2CNR1POLBEGFRGAA | |
| SCHEMBL13062814 | 0.81 | CNR2 (0.40) | CNR2CNR1EGFRGAA | |
| SCHEMBL13062817 | 0.76 | CNR2 (0.42) | CNR2CNR1 | |
| SCHEMBL3654121 | 0.75 | CNR1 (0.54) | CNR2CNR1POLBEGFRGAA | |
| SCHEMBL13062679 | 0.75 | CNR2 (0.41) | CNR2CNR1EGFRALDH1A1GAA | |
| SCHEMBL14953542 | 0.74 | CNR2 (0.53) | CNR2CNR1POLBEGFRGAA | |
| SCHEMBL13062816 | 0.74 | CNR2 (0.39) | CNR2CNR1ALDH1A1TSHR | |
| SCHEMBL14302157 | 0.74 | CNR2 (0.45) | CNR2CNR1ALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885POLB 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.